Final announcement

Precision medicine aims to tailor disease prevention, diagnosis and treatment to the individual patient, based on their individual features extracted from multiple types of data (such as multi-omics, imaging, patient history, lifestyle and environmental factors).

Advances in screening platforms and the availability of big data are fueling the scientific progress in precision medicine, spanning the early stage of drug discovery all the way through translation into clinical practice. Adequate use of statistical and computational methods are critical to its successful implementation in clinics.

The Basel Biometric Section (BBS) and the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) are pleased to host a European scientific meeting on this relevant and far-reaching topic. The purpose is to bring together experts from the pharmaceutical industry, academia and the European regulatory bodies to present the current state of the art and discuss the challenges and opportunities ahead.

The seminar takes place on June 4, 2019 from 9:00-17:00
Venue: Actelion Pharmaceuticals, Hegenheimermattweg 95, Allschwil, Switzerland



Niko Beerenwinkel, Bioinformatics for precision oncology (slide deck not available)

Stephen Senn, Precision medicine: The honeymoon is over. It’s high time for tough love

Tomasz Burzykowski, Generalized pairwise comparisons for precision medicine

Adam Heathfield, Valuation of Regenerative Medicine/Advance Therapeutics (RM/ATs): Challenges and opportunities for creating a better framework

JackKuipers, Mutational interactions define novel cancer subgroups: can they inform precision oncology?

Mario Ouwens, Difficulties with network meta-analysis when starting to use PDL1 thresholds

Georgina Bermann, Cardiovascular medicine: approaches to the use of early biomarker response to identify a patient subgroup with enhanced therapeutic benefit

Laurent Essioux, Examples of personalized Healthcare at Roche: statistical perspectives

Sorry, the comment form is closed at this time.